Webcast: Current Best Practice and Emerging Strategies for Pulmonary Arterial Hypertension
April 15, 2021
April 14, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Clinical Care Options.
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This program is intended for pulmonologists, cardiologists, and other healthcare professionals who care for patients with PAH.
The goal of this activity is to increase the knowledge and competence of learners to recognize and diagnose PAH and develop individualized treatment plans to improve patient outcomes.
Upon completion of this activity, participants should be able to:
- Recognize risk factors for PAH
- Recognize the signs and symptoms of PAH that would lead to an earlier and accurate diagnosis of PAH
- Differentiate the efficacy and safety data of currently available treatments for PAH management
- Formulate treatment plans for PAH management based on individual patient factors
Vallerie V. McLaughlin, MD
Kim A. Eagle Endowed Professor of Cardiovascular Medicine
Associate Chief Clinic Officer
Cardiovascular Medicine, Internal Medicine
University of Michigan
Ann Arbor, Michigan
Ioana R. Preston, MD
Associate Professor of Medicine
Pulmonary, Critical Care and Sleep Division
Tufts Medical Center
Director, PH Center
Tufts University School of Medicine
Physician Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Vallerie V. McLaughlin
- Funds for Research Support: Acceleron, Actelion, CiVi Biopharma, Gilead Sciences, Gossamer Bio, United Therapeutics
- Consulting Fees: Acceleron, Actelion, Altavant, Reata, Sunovion, United Therapeutics
Ioana R. Preston, MD
- Funds for Research Support : Acceleron, Actelion, PhaseBio, United Therapeutics
- Consulting Fees: Acceleron, Actelion, Pfizer, United Therapeutics
Zachary Schwartz, MSc
Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP
Vice President, Science and Strategy
Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Petra Cravens, PhD
Petra D. Cravens, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD
Associate Director, Scientific Services
Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Tanja Link, PhD
Tanja Link, PhD, has no relevant conflicts of interest to report.
Instructions for Participation and Credit
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 15, 2021, through April 14, 2022:
- Register online at http://www.clinicaloptions.com
- Read the target audience, learning objectives, and faculty disclosures.
- Study the educational activity online or printed out.
- Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Course Viewing Requirements
This program has been made available online.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For CME questions please contact: email@example.com